The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management

Cancer Cytopathology

Volumn 122, Issue 11, 2014, Pages 842-850

  Gage, Julia C ^a   Katki, Hormuzd A ^a   Schiffman, Mark ^a   Castle, Philip E ^b   Fetterman, Barbara ^c   Poitras, Nancy E ^c   Lorey, Thomas ^c   Cheung, Li C ^d   Behrens, Catherine ^e   Sharma, Abha ^e   Zhao, Fang Hui ^f   Cuzick, Jack ^g   Yang, Zi Hua ^g   Kinney, Walter K ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Global Cancer Initiative   (United States)

^c KAISER PERMANENTE   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

^e ROCHE MOLECULAR SYSTEMS   (United States)

^f PEKING UNION MEDICAL COLLEGE   (China)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

atypical squamous cells of undetermined significance (ASC US); cervical intraepithelial neoplasia (CIN); cytology; human papillomavirus (HPV)

Indexed keywords

ADULT; ARTICLE; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; CANCER GRADING; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; COLPOSCOPY; COMPARATIVE STUDY; CONTROLLED STUDY; COTEST NEGATIVE RESULT; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; HUMAN PAPILLOMAVIRUS NEGATIVE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; POPULATION RESEARCH; PRECANCER; PRIORITY JOURNAL; SCREENING TEST; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DIAGNOSIS; MASS SCREENING; MIDDLE AGED; PRACTICE GUIDELINE; PRECANCEROUS CONDITIONS; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TIME; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX DYSPLASIA; VAGINA SMEAR;

ADULT; ATYPICAL SQUAMOUS CELLS OF THE CERVIX; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPANICOLAOU TEST; PRACTICE GUIDELINES AS TOPIC; PRECANCEROUS CONDITIONS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84920828772     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21463     Document Type: Article

References (25)

1. Davey DD, Neal MH, Wilbur DC, Colgan TJ, Styer PE, Mody DR,. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2004; 128: 1224-1229.
2. Solomon D, Breen N, McNeel T,. Cervical cancer screening rates in the United States and the potential impact of implementation of screening guidelines. CA Cancer J Clin. 2007; 57: 105-111.
3. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002; 287: 2114-2119.
4. Stoler MH, Schiffman M,. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001; 285: 1500-1505.
5. Wright TC Jr, Stoler MH, Behrens CM, Sharma A, Sharma K, Apple R,. Interlaboratory variation in the performance of liquid-based cytology: insights from the ATHENA trial. Int J Cancer. 2014; 134: 1835-1843.
6. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D,; 2006 ASCCP-Sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007; 11: 201-222.
7. Massad LS, Einstein MH, Huh WK, et al. 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013; 17 (5 suppl 1): S1-S27.
8. Saslow D, Solomon D, Lawson HW, et al. ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012; 62: 147-172.
9. Moyer VA,; U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 156: 880-891, W312.
10. Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin Number 131: screening for cervical cancer. Obstet Gynecol. 2012; 120: 1222-1238.
11. American College of Obstetricians and Gynecologists. Practice Bulletin No. 140: management of abnormal cervical cancer screening test results and cervical cancer precursors. Obstet Gynecol. 2013; 122: 1338-1367.
12. Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. J Low Genit Tract Dis. 2013; 17 (5 suppl 1): S36-S42.
13. Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis. 2013; 17 (5 suppl 1): S28-S35.
14. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011; 12: 663-672.
15. Lawless JF,. Statistical Models and Methods for Lifetime Data. 2nd ed. Hoboken, NJ: John Wiley & Sons; 2002.
16. Turnbull B,. The empirical distribution function with arbitrarily grouped, censored and truncated data. J R Stat Soc B. 1976; 38: 290-295.
17. Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, Wright TL,; ATHENA (Addressing THE Need for Advanced HPV Diagnostics) HPV Study Group. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV Study. Am J Clin Pathol. 2011; 135: 468-475.
18. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000; 283: 87-93.
19. Cuzick J, Szarewski A, Mesher D, et al. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-results from the Hammersmith study. Int J Cancer. 2008; 122: 2294-2300.
20. Mesher D, Szarewski A, Cadman L, et al. Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. Br J Cancer. 2010; 102: 1405-1410.
21. Qiao Yl, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008; 9: 929-936.
22. Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001; 83: 439-444.
23. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003; 362: 1871-1876.
24. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008; 9: 425-434.
25. Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results. J Low Genit Tract Dis. 2013; 17 (5 suppl 1): S43-S49.